Cao Sisi, Weaver Connie M
Human Nutrition Program, The Ohio State University, Columbus, OH, USA.
Weaver and Associates Consulting LLC, Colorado Springs, CO, USA.
Curr Atheroscler Rep. 2022 Aug;24(8):655-661. doi: 10.1007/s11883-022-01040-8. Epub 2022 May 28.
Interest in preventing atherosclerosis and cardiovascular disease extends beyond essential nutrients and dietary patterns. This article reviews the potential for bioactive compounds to play a role in prevention and the recent process in guidance for developing policy for bioactives.
A framework for developing recommended intakes of bioactives dietary substances was recently developed and the first guideline expected is for a bioactive targeted for cardiometabolic health. Bioactives target endothelial health, the gut microbiome, serum lipids, blood pressure, inflammation, and oxidative stress. The evidence base is growing and will be enhanced further with the discovery of good biomarkers of exposure and health outcomes. A robust evidence base is essential to develop policy and influence clinical practice for bioactives, an exciting and growing area of research.
预防动脉粥样硬化和心血管疾病的兴趣已超越必需营养素和饮食模式。本文综述了生物活性化合物在预防中发挥作用的潜力以及制定生物活性物质政策指南的最新进展。
最近制定了一个制定生物活性膳食物质推荐摄入量的框架,预计首个指南将针对心脏代谢健康的生物活性物质。生物活性物质针对内皮健康、肠道微生物群、血脂、血压、炎症和氧化应激。证据基础正在不断扩大,随着暴露和健康结果的良好生物标志物的发现,将进一步得到加强。强大的证据基础对于制定生物活性物质的政策和影响临床实践至关重要,这是一个令人兴奋且不断发展的研究领域。